Fleury S.A. (BVMF:FLRY3)

Market Cap	11.35B +40.6%
Revenue (ttm)	9.09B +12.6%
Net Income	783.70M +30.5%
EPS	n/a
Shares Out	543.62M
PE Ratio	14.48
Forward PE	13.08
Dividend	1.06 (5.10%)
Ex-Dividend Date	Aug 12, 2026

Volume	5,254,000
Open	20.23
Previous Close	20.06
Day's Range	19.74 - 20.98
52-Week Range	13.90 - 28.65
Beta	0.24
Analysts	Hold
Price Target	21.99 (+5.32%)
Earnings Date	Nov 5, 2026

About Fleury

Fleury S.A., together with its subsidiaries, engages in the provision of diagnostic imaging, clinical analysis, fertility, and infusions services in Brazil. It operates in two segments, Diagnostic Medicine and Integrated Medicine. The company also provides medical services in the areas of diagnostics, laboratory support, infusions, clinical analyses, health management, healthcare, assistance medicine, orthopedics, ophthalmology, toxicological tests, fertility, infusions, and others. In addition, it operates a health platform, immunobiological d...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1926
• Employees: 29,000
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: FLRY3

Financial Performance

In 2025, Fleury's revenue was 8.29 billion, an increase of 7.89% compared to the previous year's 7.68 billion. Earnings were 612.83 million, a decrease of -0.54%.

Analyst Summary

According to 12 analysts, the average rating for FLRY3 stock is "Hold." The 12-month stock price target is R$21.99, which is an increase of 5.32% from the latest price.

Price Target

R$21.99

(5.32% upside)

Analyst Consensus: Hold

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error